Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Novartis (NVS) stock traded lower after Bank of America downgraded the Swiss drugmaker to neutral, citing a cautious outlook ...
Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.
Siemens Healthineers is planning to purchase the diagnostic arm of Novartis’ Advanced Accelerator Applications (AAA), for a sum exceeding €200m ($224m), reported Financial Times (FT).
Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...
Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...
Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based independent, discovery-stage biotech company. The collaboration has resulted in $150m Series A ...
Novartis’ blood cancer sculpture tour has reached a new destination. The Swiss drugmaker, which put the sculptures on show in London one year ago, is marking this year’s Blood Cancer Awareness ...
Novartis confirmed that it has received a binding offer from Siemens Healthineers to buy its molecular imaging business for an undisclosed amount. The Swiss pharma major said Monday that the ...